Report Feature
Gastrointestinal Drug Market Trends and Forecast
The future of the global gastrointestinal drug market looks promising with opportunities in the cure of gastro-esophageal reflux disease, inflammatory bowel disease, and irritable bowel syndrome disorders/applications. The global gastrointestinal drug market is expected to grow with a CAGR of 4%-6% from 2022 to 2027. The major drivers for this market are increasing number of gastrointestinal disorder/diseases among the old age people, increasing expenditure in the expansion of healthcare infrastructure coupled with government investment life science and the healthcare sector, and trials conducted by various pharmaceutical companies for introduction of new products.
A total of 90 figures / charts and 70 tables are provided in this 180-page report to help in your business decisions. A sample figure with insights is shown below.
Gastrointestinal Drug Market by Segment
The study includes a forecast for the global gastrointestinal drug market by drug class, route of administration, application, distribution channel, and region as follows:
Gastrointestinal Drug Market by Drug Class Type [Value ($M) shipment analysis for 2016 – 2027]:
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Antiemetic and Antinauseants
- Anti-inflammatory Drugs
- Biologics
- Others (Antispasmodic etc.)
Gastrointestinal Drug Market by Route of Administration [Value ($M) shipment analysis for 2016 – 2027]:
- Oral
- Intravenous
- Rectal
Gastrointestinal Drug Market by Application/Disorder Type [Value ($M) shipment analysis for 2016 – 2027]:
- Gastro-esophageal Reflux Disease
- Inflammatory Bowel Disease
- Irritable Bowel Syndrome
Gastrointestinal Drug Market by Distribution Channel [Value ($M) shipment analysis for 2016 – 2027]:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Gastrointestinal Drug Market by Region [Value ($M) shipment analysis for 2016 – 2027]:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Asia Pacific
- China
- Japan
- India
- The Rest of the World
List of Gastrointestinal Drug Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies gastrointestinal drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gastrointestinal drug companies profiled in this report include.
- Takeda Pharmaceuticals
- Novo Nordisk A/S
- AstraZeneca Plc
- Johnson & Johnson
- AbbVie Inc. (Allergan Plc)
- Bausch Health Companies Inc.(Valeant Pharmaceuticals Inc.)
- Bayer AG
- Boehringer Ingelheim GmbH
- GlaxoSmithKline Plc.
Gastrointestinal Drug Market Insight
- Lucintel forecasts within the global gastrointestinal drug market, the acid neutralizers will remain the largest segment and witness highest growth due to increasing consumption of antacid by growing geriatric population that are suffering from Gastroesophageal Reflux Disease (GERD), higher incidences of acidity due to unhealthy lifestyle, and side-effects of non-steroidal drugs and anti-inflammatory drugs.
- North America is expected to remain the largest market due to large number of geriatric population, lifestyles and eating habits (fast food eating), and increasing lifestyle diseases in North America region.
Features of Gastrointestinal Drug Market
- Market Size Estimates: Gastrointestinal Drug market size estimation in terms of value ($M)
- Trend and Forecast Analysis: Market trends (2016-2021) and forecast (2022-2027) by various segments and regions.
- Segmentation Analysis: Market size by drug class, route of administration, application, and distribution channel.
- Regional Analysis: Gastrointestinal Drug market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different co-catalyst type, application, and regions for the gastrointestinal drug market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape for the gastrointestinal drug market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the gastrointestinal drug market size?
Answer: The global gastrointestinal drug market is expected to reach an estimated $XX billion by 2027
Q2. What is the growth forecast for gastrointestinal drug market?
Answer: The gastrointestinal drug market is expected to grow at a CAGR of 4% to6% from 2022 to 2027.
Q3. What are the major drivers influencing the growth of the gastrointestinal drug market?
Answer: The major drivers for this market are increasing number of gastrointestinal disorder/diseases among the old age people, increasing expenditure in the expansion of healthcare infrastructure coupled with government investment life science and the healthcare sector, and trials conducted by various pharmaceutical companies for introduction of new products..
Q4. What are the major applications or end use industries for gastrointestinal drug?
Answer: Major applications include gastro-esophageal reflux disease, inflammatory bowel disease, and irritable bowel syndrome.
Q5. Who are the key gastrointestinal drug companies?
Answer: Some of the key gastrointestinal drug companies are as follows:
Q1. What is the gastrointestinal drug market size?
Answer: The global gastrointestinal drug market is expected to reach an estimated $XX billion by 2027
Q2. What is the growth forecast for gastrointestinal drug market?
Answer: The gastrointestinal drug market is expected to grow at a CAGR of 4% to6% from 2022 to 2027.
Q3. What are the major drivers influencing the growth of the gastrointestinal drug market?
Answer: The major drivers for this market are increasing number of gastrointestinal disorder/diseases among the old age people, increasing expenditure in the expansion of healthcare infrastructure coupled with government investment life science and the healthcare sector, and trials conducted by various pharmaceutical companies for introduction of new products..
Q4. What are the major applications or end use industries for gastrointestinal drug?
Answer: Major applications include gastro-esophageal reflux disease, inflammatory bowel disease, and irritable bowel syndrome.
Q5. Who are the key gastrointestinal drug companies?
Answer: Some of the key gastrointestinal drug companies are as follows:
- Takeda Pharmaceuticals
- Novo Nordisk A/S
- AstraZeneca Plc
- Johnson & Johnson
- AbbVie Inc. (Allergan Plc)
- Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
- Bayer AG
- Boehringer Ingelheim GmbH
- GlaxoSmithKline Plc.
Q6.Which gastrointestinal drug application type segment will be the largest in future?
Answer: Lucintel forecasts that acid neutralizers will remain the largest segment and witness highest growth due to increasing consumption of antacid by growing geriatric population that are suffering from Gastroesophageal Reflux Disease (GERD), higher incidences of acidity due to unhealthy lifestyle, and side effects of non-steroidal drugs and anti-inflammatory drugs.
Q7: In gastrointestinal drug market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to remain the largest region and witness the highest growth over next 5 years
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% Customization Without any Additional Cost.
This report answers following 11 key questions
Q.1 What are some of the most promising potential, high growth opportunities for the global gastrointestinal drug market by drug class (acid neutralizers, antidiarrheal and laxatives, antiemetic and antinauseants, anti-inflammatory drugs, biologics, others (antispasmodic), route of administration (oral, intravenous, rectal), application (gastro-esophageal reflux disease, inflammatory bowel disease, irritable bowel syndrome), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q. 2 Which segments will grow at a faster pace and why?
Q.3 Which regions will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the market?
Q.5 What are the business risks and threats to the market?
Q.6 What are the emerging trends in this market and the reasons behind them?
Q.7 What are the changing demands of customers in the market?
Q.8 What are the new developments in the market? Which companies are leading these developments?
Q.9 Who are the major players in this market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this area and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M & A activities have taken place in the last 5 years in this market?
Answer: Lucintel forecasts that acid neutralizers will remain the largest segment and witness highest growth due to increasing consumption of antacid by growing geriatric population that are suffering from Gastroesophageal Reflux Disease (GERD), higher incidences of acidity due to unhealthy lifestyle, and side effects of non-steroidal drugs and anti-inflammatory drugs.
Q7: In gastrointestinal drug market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to remain the largest region and witness the highest growth over next 5 years
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% Customization Without any Additional Cost.
This report answers following 11 key questions
Q.1 What are some of the most promising potential, high growth opportunities for the global gastrointestinal drug market by drug class (acid neutralizers, antidiarrheal and laxatives, antiemetic and antinauseants, anti-inflammatory drugs, biologics, others (antispasmodic), route of administration (oral, intravenous, rectal), application (gastro-esophageal reflux disease, inflammatory bowel disease, irritable bowel syndrome), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q. 2 Which segments will grow at a faster pace and why?
Q.3 Which regions will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the market?
Q.5 What are the business risks and threats to the market?
Q.6 What are the emerging trends in this market and the reasons behind them?
Q.7 What are the changing demands of customers in the market?
Q.8 What are the new developments in the market? Which companies are leading these developments?
Q.9 Who are the major players in this market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this area and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M & A activities have taken place in the last 5 years in this market?
For any questions related to gastrointestinal drug market or related to gastrointestinal drug companies, gastrointestinal drug market share, gastrointestinal drug market analysis, gastrointestinal drug market size, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents
1. Executive Summary 2. Market Background and Classifications 2.1: Introduction, Background, and Classifications 2.2: Supply Chain 2.3: Industry Drivers and Challenges
5. Competitor Analysis 5.1: Product Portfolio Analysis 5.2: Geographical Reach 5.3: Porter’s Five Forces Analysis
7. Company Profiles of Leading Players 7.1: Takeda Pharmaceuticals 7.2: Novo Nordisk A/S 7.3: AstraZeneca Plc 7.4: Johnson & Johnson 7.5: AbbVie Inc.(Allergan Plc) 7.6: Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.) 7.7: Bayer AG 7.8: Boehringer Ingelheim GmbH 7.9: GlaxoSmithKline Plc.
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
